TY  - JOUR

T1  - The economic implications of the use of basiliximab versus placebo for the control of acute cellular rejection in renal allograft recipients.

JO  - TRANSPLANTATION

PY  - 1999/04/15

AU  - Akehurst R

AU  - Chilcott J

AU  - Holmes M

ED  - 

VL  - 67

IS  - 7

SP  - S155

EP  - S155

Y2  - 2024/12/22

ER  -